NASDAQ$VIR
Vir Biotechnology Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Vir achieved several milestones, including BARDA contract and advancements in hepatitis and influenza programs.
Vir Biotechnology reported a strong third quarter with total revenues of $374.6 million, driven by collaboration revenue from sotrovimab sales and a BARDA contract. The company is advancing its pipeline with multiple Phase 2 data readouts expected in 2023 and has a strong balance sheet with approximately $2.7 billion in cash and investments.
- BARDA awarded Vir a contract with potential investment of up to $1.0 billion for infectious disease solutions.
- GSK opted-in to exclusively collaborate on the development and commercialization of antibodies against respiratory syncytial virus (RSV).
- Approximately 230,000 sotrovimab doses were delivered in Q3, all to countries outside of the US.
- Phase 2 data from hepatitis B, hepatitis D and influenza A programs are expected in 2023.
Headline financials
Revenue & EPS history
Vir · Revenue · Quarterly
$375M
Revenue by segment
Vir · $312M total across 2 segments · Q3 2022
- License & collaboration revenue$309M+201.9%99.0%
- Grant revenue$3.1M+244.4%1.0%
Forward guidance
Vir Biotechnology is focused on advancing its pipeline of product candidates targeting infectious diseases, with multiple data readouts expected in the near term. The company anticipates continued collaboration with GSK and is pursuing new therapeutic and prophylactic solutions for COVID-19 and other respiratory diseases.
Tailwinds
- Advancing key collaborations with government and industry.
- Continuing to respond to the global pandemic.
- Data expected from multiple Hepatitis B Virus (HBV) trials in the near-term.
- Novel combination strategy for Hepatitis D Virus (HDV) with significant promise for patients.
- Groundbreaking prophylaxis trial underway for Influenza.
Headwinds
- Potential for unexpected safety or efficacy data or results observed during clinical trials or in data readouts.
- Difficulties in obtaining regulatory approval.
- Uncertainty as to whether the anticipated benefits of Vir’s collaborations with other companies can be achieved.
- Delays in or disruptions to Vir’s business or clinical trials due to the COVID-19 pandemic, geopolitical changes (including the war in Ukraine) or other external factors.
- Unexpected litigation or other disputes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+2.0%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
43%
12 / 28 earnings
Positive
+27.7%
Q4 2025
Best reaction
-15.1%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -7.2% | -13.7% | |
| Q4 2025 | +27.7% | +22.3% | +20.6% | |
| Q3 2025 | -5.6% | -8.9% | +8.3% | |
| Q1 2025 | -3.4% | -16.2% | -2.9% | |
| Q4 2024 | -11.8% | -10.9% | -27.2% | |
| Q3 2024 | +21.8% | +26.8% | +4.7% | |
| Q2 2024 | -9.4% | -15.4% | -18.7% | |
| Q1 2024 | +18.9% | +13.6% | +17.5% | |
| Q4 2023 | +14.0% | +13.1% | -0.6% | |
| Q3 2023 | +12.5% | +8.3% | +24.4% | |
| Q2 2023 | -3.0% | -4.8% | -10.9% | |
| Q1 2023 | -3.5% | -4.5% | +7.5% | |
| Q4 2022 | -14.8% | -15.6% | -16.7% | |
| Q3 2022 | +15.0% | +20.3% | +23.7% | |
| Q2 2022 | +2.0% | -4.9% | -25.9% | |
| Q1 2022 | -3.1% | -1.4% | +12.5% | |
| Q4 2021 | +0.1% | -13.7% | -21.5% | |
| Q3 2021 | -15.1% | -11.7% | +20.4% | |
| Q2 2021 | +3.3% | +10.5% | +32.0% | |
| Q1 2021 | -1.0% | -8.5% | +3.5% | |
| Q4 2020 | -4.2% | -11.7% | -21.2% | |
| Q3 2020 | +8.2% | +5.8% | +26.0% | |
| Q2 2020 | -0.6% | -0.9% | -46.8% | |
| Q2 2019 | -0.6% | -0.9% | -46.8% | |
| Q1 2020 | -1.9% | -3.1% | +7.2% | |
| Q1 2019 | -1.9% | -3.1% | +7.2% | |
| Q4 2019 | +11.5% | +11.4% | +6.0% | |
| Q3 2019 | -3.0% | -0.5% | -3.7% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro